25 completed, 20 active not recruiting, 19 recruiting, 5 unknown. 77 Phase 3, 8 Phase 2.
Follow pertuzumab: new trials by email Literature Review of pertuzumab trials Research Report on pertuzumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 562 | 2027-03-09 | 2026-10-13 |
| T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd Trastuzumab deruxtecan, Trastuzumab, Pertuzumab - Advanced Breast Cancer, Metastatic Breast Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 200 | 2026-11-04 | 2026-11-17 |
| Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC Docetaxel, Pyrotinib, Trastuzumab (Herceptin) - Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Phase 3 | Recruiting | Shanghai Jiao Tong University School of Medicine | 220 | 2026-07-01 | 2026-09-01 |
| A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer BL-M07D1, Pertuzumab, Trastuzumab - HER2-positive Breast Cancer | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 596 | 2026-04-21 | 2026-06-04 |
| A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer KN026, HB1801, Trastuzumab - Resectable HER2-positive Breast Cancer | Phase 3 | Recruiting | Shanghai JMT-Bio Inc. | 1800 | 2026-03-06 | 2026-04-08 |
| A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer HLX87 + HLX22, HLX87 + Pertuzumab, T-Dxd + Pertuzumab - HER2 + Breast Cancer | Phase 2 / Phase 3 | Recruiting | Shanghai Henlius Biotech | 706 | 2026-02-27 | 2026-03-20 |
| IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer Trastuzumab, IBI354, Docetaxel - HER2-positive Breast Cancer | Phase 3 | Recruiting | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 540 | 2026-02-10 | 2026-02-25 |
| A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer HLX87+HX22, HLX87 + Pertuzumab, TCbHP - HER2 + Breast Cancer | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Henlius Biotech | 817 | 2026-01-27 | 2025-12-19 |
| A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer SHR-A1811 for Injection, Docetaxel injection, Trastuzumab Injection - Early-stage or Locally Advanced HER2-positive Breast Cancer | Phase 3 | Active not recruiting | Jiangsu HengRui Medicine Co., Ltd. | 740 | 2025-10-23 | 2026-07-30 |
| ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab Trastuzumab (Herceptin), Pertuzumab, Echocardiography - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 1524 | 2025-09-17 | 2026-10-02 |
| A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer TQB2102 for injection, Trastuzumab injection and Pertuzumab Injection and Docetaxel Injection and Carboplatin Injection - HER2-positive Breast Cancer | Phase 3 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 544 | 2025-09-15 | 2026-11-02 |
| Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer Nab paclitaxel, Docetaxel and Carboplatin, Trastuzumab + Pertuzumab - Breast Cancer | Phase 3 | Recruiting | Henan Cancer Hospital | 812 | 2025-06-24 | 2025-07-09 |
| A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer BL-M07D1, Pertuzumab, docetaxel - HER2-positive Breast Cancer | Phase 2 / Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 985 | 2025-06-05 | 2026-10-27 |
| Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer. EG1206A, Perjeta - Early Breast Cancer | Phase 3 | Withdrawn | EirGenix, Inc. | 2025-05-01 | 2025-10-14 | |
| Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer PERT-IJS plus trastuzumab, carboplatin and docetaxel, Perjeta plus trastuzumab, carboplatin and docetaxel - HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients | Phase 3 | Terminated | Biocon Biologics UK Ltd | 55 | 2025-01-06 | 2026-03-13 |
| A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer KN026, HB1801, Pertuzumab - Early or Locally Advanced HER2-positive Breast Cancer | Phase 3 | Active not recruiting | Shanghai JMT-Bio Inc. | 520 | 2024-12-16 | 2026-07-07 |
| The Sagittarius Trial Oxaliplatin, Capecitabine, Folinic acid - Colon Cancer Stage II, Colon Cancer Stage III | Phase 3 | Recruiting | IFOM ETS - The AIRC Institute of Molecular Oncology | 700 | 2024-10-22 | 2025-08-29 |
| A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer RPH-051, Docetaxel, Perjeta® - Locally Advanced Breast Cancer, Metastatic Breast Cancer | Phase 3 | Active not recruiting | R-Pharm | 246 | 2024-08-09 | 2026-07-14 |
| Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial disitamab vedotin, Pyrotinib, trastuzumab - HER2-positive Metastatic Breast Cancer, First-line Treatment | Phase 3 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 312 | 2023-09-06 | 2024-02-26 |
| Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer. Recombinant Humanized Bispecific antibody against HER2,KN026, HB1801, Pertuzumab - First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer | Phase 3 | Recruiting | Shanghai JMT-Bio Inc. | 880 | 2023-07-23 | 2025-05-30 |
Showing 20 of 77. Sign in to see all of them.
Breast Neoplasms (45) · Neoplasms (3) · Colonic Neoplasms (2) · Hematologic Neoplasms (2) · Inflammatory Breast Neoplasms (2) · Neoplasm Metastasis (2) · Ovarian Neoplasms (2) · Stomach Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Breast Diseases (1) · Carcinoma, Ductal, Breast (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Gallbladder Neoplasms (1)
Hoffmann-La Roche (18) · National Cancer Institute (NCI) (3) · Shanghai JMT-Bio Inc. (3) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (3) · AstraZeneca (2) · Cancer Research UK (2) · Fudan University (2) · Henan Cancer Hospital (2) · Japan Breast Cancer Research Group (2) · Shanghai Henlius Biotech (2) · Sichuan Baili Pharmaceutical Co., Ltd. (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Alliance Foundation Trials, LLC. (1) · Alliance for Clinical Trials in Oncology (1) · BioRay Pharmaceutical Co., Ltd. (1)
China (38) · Germany (24) · Spain (22) · United States (22) · Italy (20) · South Korea (17) · Canada (16) · France (16) · Belgium (14) · Brazil (14) · Poland (14) · Russia (14) · Japan (13) · Mexico (13) · United Kingdom (13)
Matthew Krebs, Dr (2) · Adrienne Waks, MD (1) · Andreas Schneeweiss, MD, Prof. (1) · Anja Welt, Dr. (1) · Aparna Parikh, MD (1) · Behrouz Najafi, MD (1) · Britt K Erickson (1) · Cai-Gang Liu, MD (1) · Caigang Liu, MD (1) · Charles E Geyer (1) · Clara Montagut (1) · Dr Deven Parmar, MD (1) · Fei Ma, Dr (1) · Gabe S Sonke, MD (1)
PMID 22149875, PMID 12954578, PMID 21147694, PMID 21376385, PMID 22437872, PMID 23602601, PMID 23837759, PMID 23868905, PMID 24129974, PMID 24685829, PMID 25024001, PMID 25332247, PMID 25524798, PMID 25605862, PMID 25693012, PMID 27964843, PMID 28057664, PMID 28581356, PMID 29112701, PMID 29175149, PMID 30217672, PMID 30413379, PMID 30528802, PMID 30796821, PMID 30922805, PMID 30976844, PMID 31146717, PMID 31157583, PMID 31183514, PMID 31234927, PMID 31305270, PMID 31420414, PMID 31647503, PMID 31924513, PMID 32163106, PMID 32171426, PMID 32381018, PMID 32564260, PMID 33191846, PMID 33357420, PMID 33369581, PMID 33539215, PMID 33748921, PMID 33828257, PMID 34014249, PMID 34165503, PMID 34252375, PMID 34801353, PMID 34890214, PMID 35313167
2023 (6), 2014 (3), 2017 (3), U10CA180868 (3), 2008 (1), 2009 (1), 2015 (1), U10CA012027 (1), U10CA180888 (1)